A subsequent study combining PKC inhibitor chelerythrine chloride and erlotinib in the treatment of NSCLC A549 and SK-MES1 cells reported a significant synergy in impairing cell viability, colony formation, tumor growth in xenografts, and enhanced apoptosis. Here, PRRT2 is linked to non-small cell lung carcinoma.